x
Nov2024
Ariana Pharma enters a new era with Dr. Pascale Bouillé taking the helm of the company.
Pascale Bouillé is the CEO of Ariana Pharma, where she leverages her extensive expertise in biotechnology to drive innovation and deliver impactful solutions in data-driven drug development. Her career spans significant achievements in both academia and entrepreneurship, reflecting a unique ability to transform cutting-edge scientific discoveries into successful commercial ventures.
Before joining Ariana Pharma, Pascale founded Vectalys in 2005, a company specializing in gene transfer technologies for the pharmaceutical industry. Under her leadership, Vectalys evolved into Flash Therapeutics in 2018, becoming a leading innovator in the bioproduction of DNA and RNA lentiviral technologies. Prior to her entrepreneurial journey, she contributed to groundbreaking gene therapy research at the Généthon laboratory in collaboration with Harvard Medical School, focusing on rare genetic diseases.
Pascale began her career at the Pasteur Institute, where she worked on viral mechanisms and molecular virology. She holds a PhD in molecular virology from the University Pierre and Marie Curie in Paris, laying the foundation for her illustrious career in biotechnology.
Under the leadership of Pascale Bouillé, Ariana Pharma adopts a new tagline: “Drug Development, Re-Imagine.” As an innovative and visionary player, this tagline positions us as a strategic partner capable of addressing the most complex challenges in drug development.
“By reimagining drug development, We strive to inspire a paradigm shift, we go beyond traditional probability- and statistics-based approaches. At Ariana, we deliver results grounded in logic-based rules, ensuring our analyses meet your needs precisely—and even exceed them! This new vision reflects our commitment to pushing the boundaries of innovation to deliver tangible and impactful results.” – Pascale.